Pola-R-CHP May Be Cost Effective, Depending on PFS Outcomes in Previously Untreated DLBCL
Researchers sought to determine whether combination pola-R-CHP would be cost-effective for patients with previously untreated DLBCL.
Diffuse Large B-cell Lymphoma
Bortezomib Provides No Benefit Over R-DHAP Alone in R/R DBLCL
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
Hematologists Avoid Guideline-Recommended Repeat Biopsies in Rel/Ref Diffuse Large B-Cell Lymphoma
A large proportion of patients with relapsed/refractory diffuse large B-cell lymphoma do not undergo repeat biopsy, a study suggests.
Prognostic Model Predicts Survival in Elderly With GI Diffuse Large B-Cell Lymphoma
A model including 4 clinical factors can predict overall survival, with predictive performance superior to the Ann Arbor staging system.
Model May Predict Which DLBCL Patients Will Respond to R-CHOP
Researchers sought to develop a model to classify patients with diffuse large B-cell lymphoma into prognostic subgroups.
Trial Testing Lonca-R in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase 3 trial is designed to compare loncastuximab tesirine plus rituximab with standard immunochemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
Pola-R-CHP Outperforms Standard Care for Diffuse Large B-Cell Lymphoma
Patients who received Pola-R-CHP were less likely to need subsequent treatment compared with those who received standard R-CHOP.
Naratuximab Emtansine Plus Rituximab: A New Treatment Option for Rel/Ref Non-Hodgkin Lymphoma?
The median duration of response was not reached in patients with follicular lymphoma or diffuse large B-cell lymphoma.
Tafasitamab Plus Lenalidomide May Improve Overall Survival in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
CAR T-Cell Therapies Show Similar Efficacy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Survival outcomes were comparable for patients who received tisagenlecleucel and those who received lisocabtagene maraleucel.
- Loading...
Loading...
Next post in SOHO 2021
Loading... 
Loading...